Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'

交易完善了美敦力的神经血管产品组合，在“时间就是大脑”的情况下提供简便性和可及性。

GALWAY, Ireland

爱尔兰戈尔韦

,

，

March 10, 2026

2026年3月10日

/

/

PRNewswire

美通社

/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition..

美敦力公司今天宣布达成了一项最终协议，将收购拥有神经血管领域关键创新技术的 Scientia Vascular 公司。此次收购价值 5.5 亿美元，需遵循常规调整，并有可能在收购后支付未公开的盈利能力和里程碑款项。

Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions.

Scientia是一家位于犹他州盐湖城的私营公司，拥有大约310名员工。在创始人兼现任首席技术官约翰·利珀特的带领下，该公司开发了业内领先的访问产品，为治疗复杂脑血管疾病的医生提供了简便和高效的解决方案。

Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow..

Scientia的导丝和导管产品组合可以与美敦力现有的神经血管产品套件无缝集成，增强公司支持医生在整个手术流程中的能力。

In stroke treatment, every second matters. With each second of restricted blood flow, the brain loses millions of brain cells. Today, stroke is the third leading cause of death and leading cause of disability worldwide.

在中风治疗中，每一秒都很重要。每秒钟的血液流动受阻，大脑就会失去数百万个脑细胞。今天，中风是全球第三大死亡原因和致残的主要原因。

Unlike vessels in many other parts of the body, cerebral vasculature is highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.

与身体其他许多部位的血管不同，脑血管高度复杂且迂曲，这给试图到达闭塞或动脉瘤部位的医生带来了重大挑战。难以进入可能延误治疗的实施并影响手术的成功。

Scientia's novel access platform is designed to address these challenges by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.

Scientia的新颖通路平台旨在通过改善复杂解剖结构的可导航性并简化神经血管手术来应对这些挑战。通过实现更快速、更可靠的通路，这些技术提高了手术效率。

'Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care,' said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic. 'This acquisition positions Medtronic with a full suite of products.

“美敦力非常高兴收购Scientia，以加速神经血管护理领域有意义的创新，”美敦力神经血管业务高级副总裁兼总裁林内娅·伯尔曼表示，该业务隶属于美敦力的神经科学产品组合。“此次收购使美敦力拥有了一整套产品。”

It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic's best-in-class therapies, combined with Scientia's leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world.' .

它为美敦力奠定了坚实的基础，并支持出血性卒中和急性缺血性卒中的手术。美敦力一流的治疗方案与Scientia领先的通路产品组合相结合，将展现出无比强大的力量。全球每年有1200万人遭受卒中之苦，我们期待为改善世界各地患者的预后做出贡献。

'As a company committed to improving patients' lives, we are humbled and excited for what's ahead,' said Rick Randall, CEO, Scientia. 'Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line.

“作为一家致力于改善患者生活的公司，我们对未来充满谦逊和期待，”Scientia首席执行官里克·兰德尔表示。“Scientia开发了受到医生广泛认可的关键技术。此次交易使我们能够将工程技术应用于全球范围的疾病治疗，并为美敦力提供全面的产品组合和完整的导丝系列。”

With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.'.

以美敦力的规模和影响力，能够治疗更多患者并产生更大影响的机会确实令人兴奋。

'Microwires and microcatheters are required for all neurointerventional cases,' said Dr. David Fiorella, director of the Cerebrovascular Center at Stony Brook Medicine. 'Correspondingly, better microwires and microcatheters make every single case technically easier, faster and ultimately safer for patients.

“所有神经介入手术都需要微导丝和微导管，”石溪医学脑血管中心主任大卫·菲奥雷拉博士说道。“相应地，更好的微导丝和微导管使每个病例在技术上都更简单、更快，并最终让患者更加安全。”

This revolutionary microwire technology has enabled – and will continue to enable – access and simplify the neurovascular procedures we do.'.

这种革命性的微丝技术已经实现——并将继续实现——我们所进行的神经血管手术的通路和简化。

This acquisition is expected to close in the first half of FY27, subject to regulatory approvals and satisfaction of other closing conditions. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.

预计此次收购将在2027财年上半年完成，但需获得监管部门的批准并满足其他交割条件。预计在2027财年对美敦力调整后的每股收益（EPS）影响轻微稀释，之后将转为增益。

About the Neurovascular Business at Medtronic

关于美敦力的神经血管业务

Medtronic helped create the neurovascular market – introducing innovations like liquid embolic, stent retrievers, and flow diverters. Today, with products covering multiple conditions and disease states, we work to eliminate the burden of stroke and other neurovascular diseases globally by transforming care, one breakthrough at a time.

美敦力帮助创建了神经血管市场——推出了诸如液体栓塞剂、支架取栓器和血流导向装置等创新产品。如今，我们的产品覆盖多种病症和疾病状态，通过一次次突破性创新，努力减轻中风及其他神经血管疾病带来的全球负担，变革医疗护理。

Together with our partners, including physicians, hospitals, governments and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide. For more information, follow Medtronic Neurovascular on .

与我们的合作伙伴，包括医生、医院、政府和患者一起，我们正在扩展到新的疾病状态和护理阶段。我们对更好结果的不懈关注推动了我们提供改变生命的疗法，并彻底改变全球患者的未来护理。欲了解更多信息，请关注美敦力神经血管。

LinkedIn

领英

.

。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，大胆应对人类面临的最严峻的健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的90,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、手术工具、患者监测系统等。凭借我们多元化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们做得更多，因为我们赋予洞察力驱动的护理，优先考虑人的体验，并为我们的世界带来更好的结果。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow Medtronic on

并关注美敦力

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力向证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果有重大差异。

Contacts:

联系人：

Erika Winkels

埃丽卡·温克尔斯

Ingrid Goldberg

英格丽德·戈德堡

Public Relations

公共关系

Investor Relations

投资者关系

+1-612-558-8932

+1-612-558-8932

+1-612-505-2696

+1-612-505-2696

SOURCE Medtronic plc

来源：美敦力公司